← Eichor
Condition: Uveal Melanoma Metastatic Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Uveal Melanoma Metastatic

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07627698Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
Phase 2 · 1 location(s) · University of Miami · NCT06627244Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
Phase 1 · 2 location(s) · St Vincent's Hospital, Sydney · NCT07203391Neoadjuvant Darovasertib in Primary Uveal Melanoma
Phase 3 · 94 location(s) · IDEAYA Biosciences · NCT07015190A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiat
Phase 1 · 2 location(s) · Memorial Sloan Kettering Cancer Center · NCT05607095Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Phase 2 · 3 location(s) · Diwakar Davar · NCT06070012Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
Phase N/A · 1 location(s) · Hadassah Medical Organization · NCT01438658Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
Phase 1 · 5 location(s) · MonTa Biosciences ApS · NCT04855435A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients
Phase 1 · 16 location(s) · OncoNano Medicine, Inc. · NCT06022029A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Mela
Phase 1 · 4 location(s) · Alpha-9 Oncology USA Inc. · NCT07076550Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT07276386Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma
Phase 2 · 4 location(s) · Grupo Español Multidisciplinar de Melanoma · NCT07057596Adjuvant Tebentafusp in High Risk Ocular Melanoma
Phase 3 · 15 location(s) · European Organisation for Research and Treatment of Cancer - · NCT06246149Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Phase 1/Phase 2 · 15 location(s) · IDEAYA Biosciences · NCT03947385Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
NA · 1 location(s) · Massachusetts General Hospital · NCT07364474A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Phase 1/Phase 2 · 5 location(s) · Iovance Biotherapeutics, Inc. · NCT06940739Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
Phase 1/Phase 2 · 3 location(s) · Novelwise Pharmaceutical Corporation · NCT07136181Adding IL-2 to Tebentafusp to Eradicate Cancer Progression
Phase 1/Phase 2 · 2 location(s) · St Vincent's Hospital, Sydney · NCT07063875Tebentafusp-tebn With LDT in Metastatic UM
Phase 1/Phase 2 · 1 location(s) · Thomas Jefferson University · NCT06626516Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Phase 2 · 4 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06121180Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid
Phase 1 · 3 location(s) · Anusha Kalbasi · NCT04119024A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Chec
Phase 2/Phase 3 · 33 location(s) · Replimune, Inc. · NCT06581406A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres
Phase 1 · 5 location(s) · Novelty Nobility, Inc. · NCT06805825
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.